tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BerGenBio Advances in Lung Cancer Therapy

BerGenBio Advances in Lung Cancer Therapy

BerGenBio AS (BRRGF) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

BerGenBio AS, a Norwegian biopharmaceutical firm, has reported promising developments in the clinical progress of its leading AXL inhibitor, bemcentinib, and a strong financial position with reduced operating expenses and successful capital raise through warrants exercise. The company is advancing bemcentinib’s Phase 2a study in non-small cell lung cancer, targeting a patient market estimated between $4-5 billion.

For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1